D Erkan

Summary

Affiliation: Hospital for Special Surgery
Country: USA

Publications

  1. ncbi request reprint 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends
    Doruk Erkan
    Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA Electronic address
    Autoimmun Rev 13:685-96. 2014
  2. doi request reprint A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome
    Doruk Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 65:464-71. 2013
  3. doi request reprint APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
    D Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, New York, New York, USA
    Lupus 21:695-8. 2012
  4. doi request reprint Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA
    Lupus 19:613-9. 2010
  5. ncbi request reprint Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy
    Doruk Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 47:285-90. 2002
  6. doi request reprint New approaches for managing antiphospholipid syndrome
    Doruk Erkan
    The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
    Nat Clin Pract Rheumatol 5:160-70. 2009
  7. doi request reprint Antiphospholipid Syndrome Clinical Research Task Force report
    D Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
    Lupus 20:219-24. 2011
  8. ncbi request reprint Risk quantification in antiphospholipid syndrome
    Doruk Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, USA and Hospital for Special Surgery, New York, NY, USA and Weill Medical College of Cornell University, New York, NY, USA
    Womens Health (Lond Engl) 6:179-82. 2010
  9. doi request reprint Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, NY 10021, USA
    Rheumatology (Oxford) 47:iii23-7. 2008
  10. ncbi request reprint Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals
    Doruk Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 56:2382-91. 2007

Detail Information

Publications53

  1. ncbi request reprint 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends
    Doruk Erkan
    Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA Electronic address
    Autoimmun Rev 13:685-96. 2014
    ..The report also includes recommendations for clinicians who consider using these agents in difficult-to-manage aPL-positive patients. ..
  2. doi request reprint A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome
    Doruk Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 65:464-71. 2013
    ..The secondary objectives were to evaluate the effect of rituximab on the aPL profile and to evaluate the efficacy of rituximab treatment for non-criteria manifestations of APS...
  3. doi request reprint APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
    D Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, New York, New York, USA
    Lupus 21:695-8. 2012
    ....
  4. doi request reprint Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA
    Lupus 19:613-9. 2010
    ..Furthermore, high-titer abeta(2)GPI positivity may further increase the prevalence of non-criteria aPL manifestations in moderate- or high-titer aCL-positive patients...
  5. ncbi request reprint Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy
    Doruk Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 47:285-90. 2002
    ..To conduct a pilot study to identify rheumatologists' treatment preferences for first-line rheumatoid arthritis (RA) therapy and determine whether pharmacoeconomic variables modify physician choice(s)...
  6. doi request reprint New approaches for managing antiphospholipid syndrome
    Doruk Erkan
    The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
    Nat Clin Pract Rheumatol 5:160-70. 2009
    ..Potential new approaches for the management of persistently aPL-positive patients include hydroxychloroquine, statins, rituximab, complement inhibition, and other targeted therapies that have been effective in experimental APS models...
  7. doi request reprint Antiphospholipid Syndrome Clinical Research Task Force report
    D Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
    Lupus 20:219-24. 2011
    ..An international collaborative meeting to formulate a good research question using 'FINER' (Feasible; Interesting; Novel; Ethical; and Relevant) criteria took place in November 2010...
  8. ncbi request reprint Risk quantification in antiphospholipid syndrome
    Doruk Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, USA and Hospital for Special Surgery, New York, NY, USA and Weill Medical College of Cornell University, New York, NY, USA
    Womens Health (Lond Engl) 6:179-82. 2010
    ....
  9. doi request reprint Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, NY 10021, USA
    Rheumatology (Oxford) 47:iii23-7. 2008
    ..However, the management of pregnant aPL-positive women still displays several open questions...
  10. ncbi request reprint Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals
    Doruk Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 56:2382-91. 2007
    ....
  11. doi request reprint Non-criteria manifestations of antiphospholipid syndrome
    D Erkan
    Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
    Lupus 19:424-7. 2010
    ..This brief review may help physicians in the management of the non-criteria manifestations of aPL...
  12. pmc Real world experience with antiphospholipid antibody tests: how stable are results over time?
    D Erkan
    Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 E70th Street, New York, NY 10021, USA
    Ann Rheum Dis 64:1321-5. 2005
    ....
  13. doi request reprint Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
    S S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0883, USA
    Lupus 19:475-85. 2010
    ....
  14. ncbi request reprint A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
    D Erkan
    Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York 10021, SA
    Rheumatology (Oxford) 41:924-9. 2002
    ....
  15. ncbi request reprint Cardiac involvement in the antiphospholipid syndrome
    F Tenedios
    Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
    Lupus 14:691-6. 2005
    ..The heterogeneity of APS clinical manifestations is likely linked to the varied effects that aPL can induce on endothelial cells and to the different functions that endothelial cells display depending on the anatomic localization...
  16. ncbi request reprint Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome
    D Alpert
    Department of Rheumatology, Hospital for Special Surgery, New York, USA
    Ann Rheum Dis 67:395-401. 2008
    ..To investigate the prevalence and clinical correlates of anti-heparin platelet factor 4 antibodies (anti-HPF4) in systemic lupus erythematosus (SLE) patients with and without antiphospholipid antibodies (aPL)...
  17. ncbi request reprint Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities
    Y Yazici
    Hospital for Special Surgery, Weill Medical College of Cornell University, USA
    Clin Exp Rheumatol 23:517-20. 2005
    ..To determine the frequency of liver function tests (LFT) abnormalities associated with methotrexate (MTX) use in the treatment of rheumatoid arthritis (RA)...
  18. ncbi request reprint Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report
    M Lockshin
    Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY 10021, USA
    Lupus 12:518-23. 2003
    ..Pulmonary hypertension: the Committee recommends intensive anticoagulation with warfarin and clinical trials of bosentan, epoprostenol and other new agents...
  19. ncbi request reprint Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
    Lupus 11:215-20. 2002
    ..These associations were not found with antiprothrombin antibodies. In conclusion dual autoantibodies to beta2GPI and protein S are associated with increased history of thrombosis in the antiphospholipid syndrome...
  20. pmc Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world"
    Y Yazici
    Division of Rheumatology, The Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
    Ann Rheum Dis 61:638-40. 2002
    ..To determine the incidence of disease flare during the first year of etanercept treatment for 88 patients with rheumatoid arthritis (RA) and compare it with the incidence of flare in those same patients in the year before etanercept use...
  21. ncbi request reprint Primary antiphospholipid syndrome: functional outcome after 10 years
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    J Rheumatol 27:2817-21. 2000
    ..To analyze the 10 year functional outcome of primary antiphospholipid syndrome (APS)...
  22. ncbi request reprint Reporting consistency in systemic lupus erythematosus patients: how reliable are patient histories?
    Y Yazici
    Lupus 11:46-8. 2002
    ..Our study suggests that, even though SLE patients are generally consistent reporters of certain aspects of their histories, family history information provided is frequently not consistent with previous reporting...
  23. ncbi request reprint Subclinical carotid atherosclerosis in a patient with systemic lupus erythematosus
    Deborah Alpert
    Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
    Nat Clin Pract Rheumatol 3:473-8; quiz, 2nd following 478. 2007
    ..During this time she participated in an observational study to evaluate risk factors for the development of subclinical atherosclerosis in patients with SLE...
  24. ncbi request reprint Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events
    Yusuf Yazici
    The Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Rheum 48:2769-72. 2003
    ....
  25. ncbi request reprint Cardiac manifestations in the antiphospholipid syndrome
    Felicia Tenedios
    Hospital for Special Surgery, Department of Rheumatology, Weill Medical College of Cornell University, 535 East 70 th Street, New York, NY 10021, USA
    Rheum Dis Clin North Am 32:491-507. 2006
    ..aPL may be associated with accelerated atherosclerosis in APS patients. Valve disease is the most important and most common cardiac manifestation of APS. The precise mechanism by which valves become deformed is not yet fully known...
  26. ncbi request reprint Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
    Lupus 8:560-4. 1999
    ..In both patients, bleeding stopped promptly and coagulation studies improved significantly with high dose corticosteroids. We discuss the pathogenesis, diagnosis and management of LAC-HPS in patients with SLE...
  27. pmc Long term outcome of catastrophic antiphospholipid syndrome survivors
    D Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
    Ann Rheum Dis 62:530-3. 2003
    ..The survival rate of catastrophic APS is about 50%, but the long term outcome of patients who survive is unknown...
  28. ncbi request reprint Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations
    Doruk Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Rheumatol 29:843-9. 2002
    ....
  29. ncbi request reprint The role of cardiac magnetic resonance imaging in antiphospholipid syndrome
    Doruk Erkan
    Division of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA
    J Rheumatol 29:2658-9. 2002
  30. ncbi request reprint VATER association: is it recognised by rheumatologists?
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    Clin Rheumatol 20:128-31. 2001
    ..These anomalies may become evident later in life. Therefore, in a rheumatologic practice, when evaluating patients with back pain and vertebral anomalies, one should become familiar with the varied manifestations of VATER association...
  31. pmc Assessment of the 2006 revised antiphospholipid syndrome classification criteria
    Mala Kaul
    Weill Medical College of Cornell University, New York, NY, USA
    Ann Rheum Dis 66:927-30. 2007
    ..To analyse antiphospholipid (aPL) antibody-positive patients using the 2006 revised antiphospholipid syndrome (APS) classification criteria...
  32. ncbi request reprint How much warfarin is enough in APS related thrombosis?
    Doruk Erkan
    Hospital for Special Surgery, Weill Cornell Medical College, Barbara Volcker Center, 535 E 70th Street, New York, NY 10021, USA
    Thromb Res 114:435-42. 2004
    ....
  33. ncbi request reprint Is Hughes-Stovin syndrome Behçet's disease?
    D Erkan
    Department of Rheumatology, Hospitalfor Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Exp Rheumatol 22:S64-8. 2004
    ....
  34. ncbi request reprint Protein-losing enteropathy in systemic lupus erythematosus: report of a severe, persistent case and review of pathophysiology
    Y Yazici
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
    Lupus 11:119-23. 2002
    ..We report a severe and resistant case of PLE, discuss pathophysiology and possible role of cytokines in the disease process. We also present a review of the current literature...
  35. ncbi request reprint The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus
    Ulas D Bayraktar
    Interfaith Medical Center, Brooklyn, New York, USA
    J Rheumatol 34:346-52. 2007
    ..To compare the clinical spectrum of patients with primary catastrophic antiphospholipid syndrome (P-CAPS) to those with systemic lupus erythematosus-associated CAPS (SLE-CAPS)...
  36. ncbi request reprint New treatments for antiphospholipid syndrome
    Doruk Erkan
    The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, NY 10021, USA
    Rheum Dis Clin North Am 32:129-48, x. 2006
    ..It is highly possible that the current "antithrombotic" approach to patients who are aPL-positive will be replaced by a "more specifically targeted, anti-inflammatory or immunomodulatory" approach in the future...
  37. ncbi request reprint Antiphospholipid syndrome
    Doruk Erkan
    The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, USA
    Curr Opin Rheumatol 18:242-8. 2006
    ..To review the recently published studies that can guide physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients...
  38. ncbi request reprint The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: a review of the literature and management strategies
    Doruk Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA
    Curr Rheumatol Rep 4:379-86. 2002
    ..Some data suggest that LDA might be effective against future non-gravid vascular thrombosis in patients with APS and a history of only pregnancy morbidity...
  39. ncbi request reprint Diagnostic usefulness of 3 dimensional gadolinium enhanced magnetic resonance venography in antiphospholipid syndrome
    Hale Erel
    Division of Radiology, Hospital for Special Surgery, New York, NY 10021, USA
    J Rheumatol 29:1338-9. 2002
  40. ncbi request reprint Catastrophic antiphospholipid syndrome: where do we stand?
    Doruk Erkan
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 48:3320-7. 2003
  41. ncbi request reprint New insights into pregnancy-related complications in systemic lupus erythematosus
    Doruk Erkan
    Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA
    Curr Rheumatol Rep 5:357-63. 2003
    ....
  42. ncbi request reprint What is antiphospholipid syndrome?
    Doruk Erkan
    Department of Rheumatolopgy, Hospital for Special Surgery, 535 E 70th Street, New York, NY 10021, USA
    Curr Rheumatol Rep 6:451-7. 2004
    ....
  43. ncbi request reprint Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome
    Doruk Erkan
    The Barbara Volcker Center for Women and Rheumatic Disease, Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 E70th Street, New York, NY 10021, USA
    Autoimmun Rev 6:98-103. 2006
    ..This article reviews the therapeutic and prognostic controversies that were addressed during the 1st International Symposium on CAPS...
  44. ncbi request reprint Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies: comment on the article by Sairam et al
    Doruk Erkan
    Clin Rheumatol 22:493. 2003
  45. ncbi request reprint Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator
    Arsinur Burcoglu-O'Ral
    Department of Hematology and Oncology, University of Pittsburgh, Pennsylvania, USA
    J Rheumatol 29:2006-11. 2002
    ..To define at the molecular level the vascular endothelial cell (VEC) injury characteristics of catastrophic antiphospholipid syndrome (CAPS) and to report successful therapeutic use of a VEC modulator, defibrotide...
  46. ncbi request reprint Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus
    Yusuf Yazici
    Arthritis Rheum 48:3611; author reply 3613-5. 2003
  47. ncbi request reprint Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?
    Yusuf Yazici
    J Rheumatol 29:1586-9. 2002
  48. ncbi request reprint Warfarin in antiphospholipid syndrome--time to explore new horizons
    Doruk Erkan
    J Rheumatol 32:208-12. 2005
  49. ncbi request reprint Challenges in bringing the bench to bedside in drug development for SLE
    Joan T Merrill
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street Oklahoma City, Oklahoma 73104, USA
    Nat Rev Drug Discov 3:1036-46. 2004
    ..With the current burst of drug discovery and increased public awareness of SLE, the impetus to overcome these obstacles has never been greater...
  50. ncbi request reprint Catastrophic antiphospholipid syndrome
    Setu K Vora
    Pulmonary Physicians of Norwich, Norwich, Connecticut, USA
    J Intensive Care Med 21:144-59. 2006
    ..This article reviews the current information on the etiopathogenesis, clinical manifestations, diagnosis, management, and prognosis of catastrophic antiphospholipid syndrome...
  51. ncbi request reprint Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients
    Silvia Bucciarelli
    Institut Clinic de Medicina i Dermatologia, Hospital Clinic, Barcelona, Catalonia, Spain
    Arthritis Rheum 54:2568-76. 2006
    ..To assess the main causes of death and the prognostic factors that influence mortality in patients with the catastrophic antiphospholipid syndrome (CAPS)...
  52. ncbi request reprint Lupus and thrombosis
    Doruk Erkan
    J Rheumatol 33:1715-7. 2006
  53. ncbi request reprint Treatment of the antiphospholipid syndrome
    Michael D Lockshin
    N Engl J Med 349:1177-9. 2003